FDA approves Moderna's mRNA-based flu vaccine for adults aged 50 and older
PBS · August 6, 2026Original source ↗
What happened
The FDA has approved a new flu vaccine developed by Moderna, named mFlusiva, which is designed for adults aged 50 and older. This approval allows for the vaccine to be made available for public use.
Why it matters
The approval of this vaccine could enhance flu prevention efforts among older adults.
How this story affects people
How does this story affect you if you are a retiree?
This approval directly affects retirees aged 50 and older, as they are the primary target group for the new flu vaccine. Increased flu prevention could lead to better health outcomes and fewer hospitalizations during flu season.
How does this story affect you if you are a patient?
Patients aged 50 and older may benefit from the new flu vaccine, as it provides an additional option for flu prevention. This could lead to reduced illness and healthcare visits related to the flu.
How does this story affect you if you are a parent?
Parents of children or young adults may be indirectly affected by this approval, as improved flu prevention in older adults could reduce the overall flu transmission in communities. This may help protect younger family members who are more vulnerable to severe flu complications.
Want this written about you?
The breakdown above is the shared version, for kinds of people. In the app, Ripple uses your job, your city, and your family, then writes that part about you.
Get your RippleMore stories
- HealthEbola outbreak in Democratic Republic of Congo sees significant rise in cases and deaths
- HealthTrump proposes splitting combination vaccines into separate injections
- HealthEbola outbreak in DRC spreads to sixth province
- HealthSurrogate gives birth in Texas to baby with heart defect after fleeing from California